← Eichor
Study identifier: NCT07058779 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Safety, Tolerability, PK and PD of SSS55 in Healthy Subjects

Condition: Safety Issues  ·  Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.

PhasePhase 1
Planned participants26
Who can joinAll sexes, 18 Years to 45 Years
Healthy volunteersYes

About this study

This study was a single-dose, randomized, double-blind, placebo-controlled study of SSS55 injection to evaluate the safety, tolerability, PK characteristics, immunogenicity and preliminary efficacy characteristics of single-dose SSS55 injection in healthy individuals.

This description comes directly from the study's public registry record.

Talk to the study team

Ding Chief Pharmacist, Doctor of Medicine  ·  86-13761642319  ·  shiyiphase1@126.com

Always discuss trial participation with your own doctor first.

Locations (1)

Shanghai General HospitalShanghai, Shanghai Municipality, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07058779